Article Details
Retrieved on: 2021-01-12 17:03:53
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In October 2016, Milo Biotechnology received the Orphan Drug designation from the U. S. FDA for AAV1-FS344, a follistatin protein product used for ...
Article found on: ksusentinel.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here